Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

137.20 -0.79 (-0.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 481,890
Open 139.75
Bid (Size) 98.00 (1)
Ask (Size) 154.00 (1)
Prev. Close 137.99
Today's Range 135.46 - 140.71
52wk Range 102.97 - 182.52
Shares Outstanding 55,679,964
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Deep Dive Into Repligen Stock: Analyst Perspectives (8 Ratings)
Via Benzinga
RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 10.4% year on year to $169.2 million. The company’s... 
Via StockStory
Topics World Trade
Exposures Tariff

Performance

YTD
-4.1%
-4.1%
1 Month
+6.8%
+6.8%
3 Month
-18.1%
-18.1%
6 Month
+2.2%
+2.2%
1 Year
-13.4%
-13.4%

More News

Read More
Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations
Via StockStory
Topics World Trade
Exposures Tariff
Earnings Scheduled For April 29, 2025
Via Benzinga
The Analyst Verdict: Repligen In The Eyes Of 4 Experts
Via Benzinga
Earnings Scheduled For February 20, 2025
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Repligen (RGEN) Q1 Earnings: What To Expect
Via StockStory
Topics World Trade
Exposures Tariff
3 Healthcare Stocks That Concern Us
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings?
Via StockStory
Topics Stocks
Exposures US Equities
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
Via StockStory
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
Via StockStory
Demystifying Repligen: Insights From 6 Analyst Reviews
Via Benzinga
Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks
Via StockStory
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
Via StockStory
3 Small-Cap Stocks Skating on Thin Ice
Via StockStory
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth
Via Benzinga
Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook
Via Benzinga
Repligen's Q4 Slightly Tops Expectations
Via The Motley Fool
Repligen (NASDAQ:RGEN) Posts Q4 Sales In Line With Estimates
Via StockStory
Exposures COVID-19
Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow
Via StockStory
3 Healthcare Stocks Skating on Thin Ice
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth
Via Benzinga
Topics Earnings
Exposures Financial
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga

Frequently Asked Questions

Is Repligen Corporation - Common Stock publicly traded?
Yes, Repligen Corporation - Common Stock is publicly traded.
What exchange does Repligen Corporation - Common Stock trade on?
Repligen Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Repligen Corporation - Common Stock?
The ticker symbol for Repligen Corporation - Common Stock is RGEN on the Nasdaq Stock Market
What is the current price of Repligen Corporation - Common Stock?
The current price of Repligen Corporation - Common Stock is 137.20
When was Repligen Corporation - Common Stock last traded?
The last trade of Repligen Corporation - Common Stock was at 05/01/25 04:00 PM ET
What is the market capitalization of Repligen Corporation - Common Stock?
The market capitalization of Repligen Corporation - Common Stock is 7.64B
How many shares of Repligen Corporation - Common Stock are outstanding?
Repligen Corporation - Common Stock has 8B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.